Entrada Therapeutics’ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEV™ technology, Entrada is creating a diverse pipeline of enzyme, oligonucleotide, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada, a privately-held company, raised $59 million in a Series A financing in December 2018. The financing was co-led by 5AM Ventures and MPM Capital, along with Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit www.entradatx.com.